How are NKTR straddle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the NKTR straddle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 68.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$436.82 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a NKTR straddle?

The breakeven for the NKTR straddle priced on this page is roughly $70.48 and $79.53 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The NKTR market-implied 1-standard-deviation expected move in the same options snapshot is approximately 19.50%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current NKTR implied volatility affect this straddle?

NKTR ATM IV is at 68.00% with IV rank near 14.06%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

NKTR Straddle Strategy

NKTR (Nektar Therapeutics), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer.

NKTR (Nektar Therapeutics) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.09B, a beta of 1.16 versus the broader market, a 52-week range of 25.34-109, average daily share volume of 1.0M, a public-listing history dating back to 1994, approximately 63 full-time employees. These structural characteristics shape how NKTR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.16 places NKTR roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a straddle on NKTR?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

NKTR snapshot

As of August 14, 2026, spot at $73.31, ATM IV 68.00%, IV rank 14.06%, expected move 19.50%. The straddle on NKTR below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 7-day expiry.

Why this straddle structure on NKTR specifically: NKTR IV at 68.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a NKTR straddle, with a market-implied 1-standard-deviation move of approximately 19.50% (roughly $14.29 on the underlying). The 7-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NKTR expiries trade a higher absolute premium for lower per-day decay. Position sizing on NKTR should anchor to the underlying notional of $73.31 per share and to the trader's directional view on NKTR stock.

NKTR straddle setup

The NKTR straddle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NKTR at $73.31 on that close, the first option leg uses a $75.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NKTR chain at a 7-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NKTR shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$75.00	$1.63
Buy 1	Put	$75.00	$2.90

NKTR straddle risk and reward

Net Premium / Debit: -$452.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$436.82
Breakeven(s): $70.48, $79.53
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

NKTR straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on NKTR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$7,046.50
$16.22	-77.9%	+$5,425.69
$32.43	-55.8%	+$3,804.87
$48.63	-33.7%	+$2,184.06
$64.84	-11.6%	+$563.24
$81.05	+10.6%	+$152.57
$97.26	+32.7%	+$1,773.38
$113.47	+54.8%	+$3,394.20
$129.68	+76.9%	+$5,015.01
$145.88	+99.0%	+$6,635.83

When traders use straddle on NKTR

Straddles on NKTR are pure-volatility plays that profit from large moves in either direction; traders typically buy NKTR straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

NKTR thesis for this straddle

The market-implied 1-standard-deviation range for NKTR extends from approximately $59.02 on the downside to $87.60 on the upside. A NKTR long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current NKTR IV rank near 14.06% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NKTR at 68.00%. As a Healthcare name, NKTR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NKTR-specific events.

NKTR straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NKTR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NKTR alongside the broader basket even when NKTR-specific fundamentals are unchanged. Always rebuild the position from current NKTR chain quotes before placing a trade.

Frequently asked questions

What is a straddle on NKTR?: A straddle on NKTR is the straddle strategy applied to NKTR (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With NKTR stock at $73.31 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed NKTR chain strike and the premiums come straight from that session's bid/ask midpoint.
How are NKTR straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the NKTR straddle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 68.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$436.82 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a NKTR straddle?: The breakeven for the NKTR straddle priced on this page is roughly $70.48 and $79.53 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The NKTR market-implied 1-standard-deviation expected move in the same options snapshot is approximately 19.50%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on NKTR?: Straddles on NKTR are pure-volatility plays that profit from large moves in either direction; traders typically buy NKTR straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current NKTR implied volatility affect this straddle?: NKTR ATM IV is at 68.00% with IV rank near 14.06%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.